Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1

Conditions

Breast Neoplasms 41Carcinoma, Renal Cell 31Neoplasms 18Kidney Neoplasms 17Neuroendocrine Tumors 16Neoplasm Metastasis 13Tuberous Sclerosis 10Prostatic Neoplasms 8Carcinoma 8Lymphoma, Mantle-Cell 7Lymphoma, Large B-Cell, Diffuse 7Hodgkin Disease 7Glioma 7Glioblastoma 7Astrocytoma 7Waldenstrom Macroglobulinemia 6Triple Negative Breast Neoplasms 6Recurrence 6Lymphoma 6Head and Neck Neoplasms 6Stomach Neoplasms 5Ovarian Neoplasms 5Colorectal Neoplasms 5Carcinoma, Neuroendocrine 5Brain Neoplasms 5Sezary Syndrome 4Sarcoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Pancreatic Neoplasms 4Mycosis Fungoides 4

Interventions

Sunitinib 16Imatinib Mesylate 13nilotinib 8ripretinib 4regorafenib 4avapritinib 34-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 3pexidartinib 2pembrolizumab 2Bevacizumab 2trametinib 1tinostamustine 1spartalizumab 1romidepsin 1ponatinib 1pazopanib 1palbociclib 1olaratumab 1guadecitabine 1ferric carboxymaltose 1epacadostat 1dabrafenib 1cediranib 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Sorafenib 1STA 9090 1Observation 1Iron-Dextran Complex 1Indocyanine Green 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gastrointestinal Stromal Tumors × Everolimus × Clear all
NCT01275222 2021-06-25

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

Novartis

Phase 1/2 Completed
117 enrolled 18 charts
GastrointestinalSarcoma

Digestive System Neoplasms, Sarcoma, Stomach Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡